We commend @RepKatiePorter for raising concerns about the Quality Adjusted Life Years (QALY) methodology. We know the QALY discriminates against Californians with disabilities, patients with cancer or a rare disease, and seniors. Federal policymakers must avoid ICER and the QALY.
“Unfortunately, sometimes that critical medication selection is taken away from physicians by insurance companies that want patients to try other medications first” #steptherapy #AB347 @CalMatters https://bit.ly/3quDS2y
California lawmakers should address health disparities, stem rise in prostate cancer https://pajaronian.com/california-lawmakers-should-address-health-disparities-stem-rise-in-prostate-cancer/ via @pajaronian support #AB1520 @bretanmd
Success: Assembly Bill 1520 passes Health Committee Hearing in 10 to 0 vote. Our first hurdle to no cost PSA Screening in Calif. Thank you to bill sponsors Assemblymember Marc Levine @AsmMarcLevine and Sen. Ben Allen @senatorbenallen and all who helped with your support.
Take Action today on PSA Screening in California! Support Assembly Bill 1520
This bill will save lives and help lessen healthcare disparities! Take Action Link: https://p2a.co/wllx3og
More info https://cuanet.org/support-ab1520/
There are several bipartisan federal policy proposals, like #HR4597 and #HR6179, cosponsored by CA representatives, that promote increased use of #biosimilars to benefit patients, providers, and budgets while preserving physician and patient choice.
Excellent panel at @SDChamber today discussing health care cost-savings possibilities like #biosimilars. CA has the potential to save hundreds of millions of dollars annually by increasing access to biosimilar medicines in the state.